The oral ulcer drug market was valued at USD 984.8 Mn by 2019. Rising prevalence of oral infection primarily drives the oral ulcer drug market growth. Furthermore, the flourishing persona care and consumer healthcare segment across the globe further accentuates the market growth.

As per the latest research findings postulated by the International Dental Association (IDA), the major factors responsible for the occurrence of oral ulcers attrition with sharp teeth, accidental biting of the inside of your cheek, poor oral hygiene, and burns from eating hot food. The presence of mucosal irritants such as tobacco products, betel nuts for a longer period of time can aggravate the occurrence of painful mouth lesions. Positive marketing strategy to educate consumers worldwide pertaining to the importance of oral health & hygiene and increasing disposable income in low and middle-income countries further propels the oral ulcer drug market growth.

The major segments related to the oral ulcer drug market are: 

By Drug Class (2017–2027; US$ Mn)

Antihistamine

Antimicrobial

Analgesic

Corticosteroid

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global oral ulcer drug market
• The overall segmentation of the oral ulcer drug market, by drug class, distribution channel, and geography is minutely studied. Analgesic and hospital pharmacy are dominating the drug class and distribution channel segments respectively
• Rising prevalence of oral infection worldwide
• Significant increase in the clinical trial investigation to the pathophysiology of oral ulcers and determine the therapeutic efficacy of novel drug molecules for their treatment

Report gist?

• The study of the global oral ulcer drug market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of drug class and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of oral ulcer drug due to the  rising prevalence of oral infection worldwide
• The report will benefit formulation scientist actively engaged in making drug formulations for the treatment of oral ulcers across the globe
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to the oral ulcer drug market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Analgesics are currently dominating the drug class market for the oral ulcer drugs market. A significant increase in the number of individuals suffering from aphthous ulcers has led to the increasing demand for analgesics to relieve the excruciating pain the most widely preferred analgesics for the treatment of oral ulcers are lignocaine hydrochloride, benzocaine, etc. Corticosteroids will be highlighting exemplary market performance in the near future on account of its anti-inflammatory properties in the treatment of canker sores. The corticosteroids used in drug formulation for the treatment of oral ulcers are Hydrocortisone hemisuccinate, Triamcinolone acetonide, and Betamethasone sodium phosphate.

Hospital pharmacy is representing the largest market share in the oral ulcer drug market. The majority of drug formulations intending for the treatment of oral infections contain schedule H and schedule X drugs which need to be taken under the medical supervision of a hospital pharmacist. Retail pharmacy is expected to highlight sturdy market growth during the forecast period owing to the flourishing personal and consumer care products and the provision of essential medicines at a low price.

North America is currently leading the geography segment for the oral ulcer drug market. The growing incidence of oral infection primarily drives the market growth of oral ulcer drugs in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), the prevalence rate associated with oral ulceration in the United States is 4%. Furthermore, the favorable reimbursement scenario associated with the oral ulcer drugs and domicile of key players in the region such as 3M Company, Reckitt Benckiser, Colgate-Palmolive Company, Church & Dwight Co, Inc., etc., further accentuates the market growth in the region. Europe is considered as the second-largest regional segment for the oral ulcer drug market owing to the nurturing regulatory environment provided by the European Medical Agency (EMA), for the sale and distribution of oral ulcer drugs in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for oral ulcer drugs market on account of the rising prevalence of oral infection due to poor hygiene, chewing of tobacco, betel nuts, etc., and flourishing personal and consumer healthcare segment.